- Home
- IAC vs ADMA Comparison
IAC vs ADMA Comparison
Compare IAC & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IAC
- ADMA
- Stock Information
- Founded
- IAC N/A
- ADMA 2004
- Country
- IAC United States
- ADMA United States
- Employees
- IAC N/A
- ADMA N/A
- Industry
- IAC Computer Software: Programming Data Processing
- ADMA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IAC Technology
- ADMA Health Care
- Exchange
- IAC Nasdaq
- ADMA Nasdaq
- Market Cap
- IAC 4.5B
- ADMA 4.1B
- IPO Year
- IAC 1992
- ADMA N/A
- Fundamental
- Price
- IAC $42.50
- ADMA $17.40
- Analyst Decision
- IAC Buy
- ADMA Strong Buy
- Analyst Count
- IAC 13
- ADMA 4
- Target Price
- IAC $68.69
- ADMA $21.25
- AVG Volume (30 Days)
- IAC 731.3K
- ADMA 2.8M
- Earning Date
- IAC 02-11-2025
- ADMA 11-07-2024
- Dividend Yield
- IAC N/A
- ADMA N/A
- EPS Growth
- IAC N/A
- ADMA N/A
- EPS
- IAC N/A
- ADMA 0.28
- Revenue
- IAC $3,875,960,000.00
- ADMA $382,809,000.00
- Revenue This Year
- IAC N/A
- ADMA $66.84
- Revenue Next Year
- IAC N/A
- ADMA $14.72
- P/E Ratio
- IAC N/A
- ADMA $62.07
- Revenue Growth
- IAC N/A
- ADMA 63.39
- 52 Week Low
- IAC $41.08
- ADMA $4.16
- 52 Week High
- IAC $58.29
- ADMA $23.64
- Technical
- Relative Strength Index (RSI)
- IAC 24.52
- ADMA 36.96
- Support Level
- IAC $41.08
- ADMA $17.32
- Resistance Level
- IAC $49.71
- ADMA $18.97
- Average True Range (ATR)
- IAC 1.30
- ADMA 0.75
- MACD
- IAC -0.49
- ADMA -0.30
- Stochastic Oscillator
- IAC 5.79
- ADMA 10.32
About IAC IAC Inc.
IAC is an internet media company with segments that include Angi (33% of total revenue), Dotdash Meredith (39%), search (14%), and emerging and other (14%). The firm spun off the narrow-moat dating app provider Match Group in second-quarter 2020 and the no-moat video software provider Vimeo in second-quarter 2021.
About ADMA ADMA Biologics Inc
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.